炎症性肠病治疗相关的严重感染与机会性感染风险
基于法国全国医疗保险数据库2009年1月1日至2014年12月31日纳入的190,694例成人炎症性肠病(IBD)患者,采用边际结构Cox比例风险模型比较联合治疗、抗TNF单药和硫嘌呤单药治疗的感染风险。联合治疗较抗TNF单药增加严重感染和机会性感染风险;抗TNF单药较硫嘌呤单药增加严重感染、分枝杆菌感染和细菌感染风险,但降低机会性病毒感染风险。
要点
- 联合治疗较抗TNF单药增加严重感染(HR 1.23)和机会性感染(HR 1.96)风险。
- 抗TNF单药较硫嘌呤单药增加严重感染(HR 1.71)、分枝杆菌感染(HR 1.98)和细菌感染(HR 2.38)风险。
- 抗TNF单药较硫嘌呤单药降低机会性病毒感染风险(HR 0.57)。
核心结论
- 在法国全国IBD队列中,免疫抑制方案治疗的患者严重感染和机会性感染风险存在异质性,临床管理时应仔细考虑并与IBD治疗的潜在获益权衡。
研究设计与样本
- 法国全国性基于人群的研究,纳入法国国家医疗保险数据库中18岁及以上诊断为IBD的患者,数据收集自2009年1月1日至2014年12月31日。
- 共纳入190,694例IBD患者,采用边际结构Cox比例风险模型,调整基线及随时间变化的 sociodemographic 特征、药物和合并症。
主要发现
- 分析期间共发生8561例严重感染和674例机会性感染。
- 与抗TNF单药相比,联合治疗严重感染风险升高(HR 1.23;95%CI 1.05-1.45),机会性感染风险升高(HR 1.96;95%CI 1.32-2.91)。
- 与硫嘌呤单药相比,抗TNF单药严重感染风险升高(HR 1.71;95%CI 1.56-1.88),分枝杆菌感染风险升高(HR 1.98;95%CI 1.15-3.40),细菌感染风险升高(HR 2.38;95%CI 1.23-4.58)。
- 与硫嘌呤单药相比,抗TNF单药机会性病毒感染风险降低(HR 0.57;95%CI 0.38-0.87)。
临床怎么用
- 原文未据此给出推荐,作者在结论中指出免疫抑制方案的感染风险存在异质性,临床管理时应仔细考虑并与IBD治疗的潜在获益权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The risk of infection associated with tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of serious and opportunistic infections in patients with inflammatory bowel disease (IBD) treated with thiopurine monotherapy, anti-TNF monotherapy, or combination therapy in a large cohort of patients in France. METHODS: We performed a nationwide population-based study of patients (18 years or older) with a diagnosis of IBD in the French national health insurance database; we collected data from January 1, 2009 until December 31, 2014. The risks of serious and opportunistic infections associated with exposure to combination therapy, anti-TNF, and thiopurine monotherapies were compared using marginal structural Cox proportional hazard models adjusted for baseline and time-varying sociodemographic characteristics, medications, and comorbidities. RESULTS: Among the 190,694 patients with IBD included in our analysis, 8561 serious infections and 674 opportunistic infections occurred. Compared with anti-TNF monotherapy, combination therapy was associated with increased risks of serious infection (hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.05-1.45) and opportunistic infection (HR, 1.96; 95% CI, 1.32-2.91). Compared with thiopurine monotherapy, anti-TNF monotherapy was associated with increased risks of serious infection (HR, 1.71; 95% CI, 1.56-1.88), mycobacterial infection (HR, 1.98; 95% CI, 1.15-3.40), and bacterial infection (HR, 2.38; 95% CI, 1.23-4.58, respectively). Conversely, anti-TNF monotherapy was associated with decreased risk of opportunistic viral infection compared with thiopurine monotherapy (HR, 0.57; 95% CI, 0.38-0.87). CONCLUSIONS: In a nationwide cohort study of patients with IBD in France, we found heterogeneity in risks of serious and opportunistic infections in patients treated with immune-suppressive regimens. These should be carefully considered and weighed against potential benefits for IBD treatment in patient management.
引用
- Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018. PMID: 29655835. doi:10.1053/j.gastro.2018.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。